<?xml version="1.0" encoding="UTF-8"?><REUTERS CGISPLIT="PUBLISHED-TESTSET" LEWISSPLIT="NOT-USED" NEWID="16994" OLDID="21644" TOPICS="NO">
<DATE>21-APR-1987 10:57:51.31</DATE>
<TOPICS/>
<PLACES><D>usa</D></PLACES>
<PEOPLE/>
<ORGS/>
<EXCHANGES/>
<COMPANIES/>
<UNKNOWN> 
   F
   f1230 reute
u f BC-ALFIN-&lt;AFN&gt;-DRUG-MISL   04-21 0109</UNKNOWN>
<TEXT> 
<TITLE>ALFIN &lt;AFN&gt; DRUG MISLABELLED, SAYS FDA</TITLE>
<DATELINE>    NEW YORK, April 21 - </DATELINE><BODY>Alfin Inc &lt;AFN&gt; said it has received a
regulatory letter from the Office of Compliance of the U.S.
Food and Drug Administration asserting that because of
labelling and certain advertising claims its Glycel products
are "new drugs" within the meaning of the Federal Food, Drug
and Cosmetic Act for which no approval has been obtained and
are "misbranded" in their labelling.
    The company said it understands that this action is part of
an industry-wide investigation.
    The company added it is reviewing the matter with counsel,
intends to respond and take corrective action, if necessary.
 Reuter
 </BODY></TEXT>
</REUTERS>